Cargando…
Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors
Autores principales: | Hsu, Wan-Hsuan, Tsai, Ya-Wen, Wu, Jheng-Yan, Liu, Ting-Hui, Lai, Chih-Cheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911974/ https://www.ncbi.nlm.nih.gov/pubmed/36773894 http://dx.doi.org/10.1016/j.jinf.2023.02.007 |
Ejemplares similares
-
Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 for patients with dementia
por: Liu, Ting-Hui, et al.
Publicado: (2023) -
The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: A retrospective cohort study including 91,528 patients
por: Liu, Ting-Hui, et al.
Publicado: (2023) -
Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase()
por: Wan, Eric Yuk Fai, et al.
Publicado: (2023) -
The effect of molnupiravir on post-acute outcome of COVID-19 survivors
por: Hsu, Wan-Hsuan, et al.
Publicado: (2023) -
Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)